Results 121 to 130 of about 1,993,579 (343)

Drug-drug interactions in prescriptions of Lorestan province, Western of Iran [PDF]

, 2015
Rational prescribing means prescribing the more effective and healthiest drug for a disease according to patient’s condition, the type of effective drugs, cost and etc.
Adineh, Ahmad., Asadbeigi, Mohsen., Bahmani, Mahmoud., Bahram, Delfan., Changizian, Sehar., Rafieian-Kopaei, Mahmoud.   +5 more
core  

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis [PDF]

, 2018
Background and aims: Patients with liver cirrhosis may be at risk for potential drug-drug interactions (pDDIs) and/or adverse drug reactions (ADRs) due to the severity of their disease and comorbidities associated with polypharmacy. Methods: We performed
Born, Christa, Egger, Sabin, Franz, Carmen, Krähenbühl, Stephan, Rätz Bravo, Alexandra   +4 more
core  

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Editorial: Drug-drug interactions in pharmacology

Frontiers in Pharmacology, 2023
Simona Pichini, Annagiulia Di Trana, Oscar García-Algar, Francesco Paolo Busardò   +3 more
doaj   +1 more source

Drug–Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats

Drug Design, Development and Therapy, 2019
Qiong Wang,1 Haiyun Wang,1 Youyan Zhong,1 Qiang Zhang2 1Department of Pharmacy, Wenzhou People’s Hospital, Wenzhou, Zhejiang 325000, People’s Republic of China; 2Department of Clinical Laboratory, The People’s Hospital of Lishui, Lishui,
Wang Q, Wang H, Zhong Y, Zhang Q
doaj  

Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine

, 2021
Linda Al‐Hassany, Antoinette MaassenVanDenBrink   +1 more
openalex   +1 more source

Pharmacokinetic drug–drug interactions with direct anticoagulants in the management of cancer‐associated thrombosis [PDF]

, 2023
Lorenz Van der Linden, Thomas Vanassche, Eric Van Cutsem, Lucas Van Aelst, Peter Verhamme   +4 more
openalex   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Drug–Drug Interactions of FXI Inhibitors: Clinical Relevance

Hematology Reports
Inhibitors of the factor FXI represent a new class of anticoagulant agents that are facing clinical approval for the treatment of acute coronary syndrome (ACS), venous thromboembolism (VTE), and stroke prevention of atrial fibrillation (AF).
Nicola Ferri, Elisa Colombo, Alberto Corsini   +2 more
doaj   +1 more source